Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-3583 in Advanced Solid Tumors
NCT04747470Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GS-3583 in solid tumor (advanced stage), head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) (11 arms), sponsored by Gilead Sciences. Primary endpoints: Dose Limiting Toxicities, Treatment-Emergent Adverse Events up to 4 months and 2 more. Started Mar 2021; status: terminated.
02
Drugs
GS-3583
03
Conditions
solid tumor (advanced stage)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04747470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747470.